Abstracts tagged "IL-6 and rheumatoid arthritis (RA)"

Abstract Number: 1597 • 2016 ACR/ARHP Annual Meeting
Dose-Response Modeling Is a Useful Tool to Determine Doses for Phase 3: Experience from Olokizumab
Russell Reeve¹, Doris Weilert², Elena Korneva³, Dmitry Koloda³ and Saeed Fatenejad⁴, ¹Quintiles, Inc., Durham, NC, ²Quintiles, Inc., Kansas City, MO, ³R-Pharm CJSC, Moscow, Russian Federation, ⁴Fatenejad Consultancy, Miami, FL
Background/Purpose: Olokizumab (OKZ) is an anti-interleukin-6 (IL-6) monoclonal antibody in development for the treatment of rheumatoid arthritis (RA). In phase 2 studies, treatment with OKZ+methotrexate…
Abstract Number: 1735 • 2013 ACR/ARHP Annual Meeting
A Phase IIb Study Of The Efficacy and Safety Of Subcutaneous Clazakizumab (anti-IL-6 monoclonal antibody) With Or Without Methotrexate In Adults With Moderate-To-Severe Active Rheumatoid Arthritis and An Inadequate Response To Methotrexate
M Weinblatt¹, Philip Mease², E Mysler³, T Takeuchi⁴, E Drescher⁵, A Berman⁶, M Zilberstein⁷, J Xing⁷ and P Emery⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Keio University, Tokyo, Japan, ⁵Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁶Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: Clazakizumab (claza) is a humanized anti-interleukin-6 (IL-6) monoclonal antibody that potently neutralizes IL-6 signaling. This study evaluated the safety and efficacy of subcutaneous claza…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].